More Mesoblast Limited news
Mesoblast LimitedASX: MSB

Mesoblast provides update on clinical programs of prochymal

Mar 30, 2016 at 4:09 AM EDT · Issued by Mesoblast Limited

Filed with ASX · Mar 30, 2016 at 4:09 AM EDT

On 6ix: 6ix.com/news/mesoblast-provides-update-on-clinical-programs-of-prochymal

Watch Mesoblast's latest call↗Mesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call↗

View Attachment

6ix hasn’t read this filing yet.

Mesoblast Limited on 6ix

Earlier from Mesoblast

  • MSB & NIH Agree 120 Patient Trial In End-Stage Heart FailureMar 30, 2016
  • MSB Accelerates Plans for Commercial Manufacturing OperationMar 30, 2016
  • Mesoblast Receives $5.05m for Stem Cell Pipeline DevelopmentMar 30, 2016
  • Circulation Publishes Improved Outcomes with Mesoblast CellsMar 30, 2016
  • Key US Patent Granted For Treatment Of Rheumatoid ArthritisMar 23, 2016

Later from Mesoblast

  • Half-Year Results & Strategic Update on Product DevelopmentMar 30, 2016
  • Key mpc patents granted in united states and chinaMar 30, 2016
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer